Longitudinal Analysis of Clinical Outcomes in PiMZ Alpha-1 Antitrypsin Smokers From the Spiromics Cohort
B22. NEW TREATMENTS AND NOVEL TARGETS FOR COPD AND ALPHA-1 | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A2840-A2840